Public medtech companies failed to reach predicted milestones toward the end of 2024, particularly in life sciences where all but one major firm experienced share price declines greater than 7%. Exits were also muted in Q4, but PitchBook’s analysts expect an uptick in both exits and M&A activity in 2025 on the back of reduced antitrust activity and innovation in areas such as wearable medical devices.
Read the full article: PitchBook’s Q4 2024 Medtech Public Comp Sheet and Valuation Guide //
Source: https://pitchbook.com/news/reports/q4-2024-medtech-public-comp-sheet-and-valuation-guide